Literature DB >> 9049229

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.

K Chayama1, A Tsubota, M Kobayashi, K Okamoto, M Hashimoto, Y Miyano, H Koike, M Kobayashi, I Koida, Y Arase, S Saitoh, Y Suzuki, N Murashima, K Ikeda, H Kumada.   

Abstract

Hepatitis C virus (HCV) genotype 1b and high pretreatment virus load are predictive factors of poor response to interferon therapy in patients with chronic hepatitis C. To further examine the factors predicting the response to interferon in patients with genotype 1b infection, we analyzed 110 consecutive patients with HCV who were treated with a total of 624 million units of lymphoblastoid interferon alfa. Thirty-six patients (33%) were responders, while the remaining 74 patients (67%) were nonresponders. Multivariate analysis showed that a high virus titer (assessed by serum core protein level, P = .0021) and the presence of more than two amino acid substitutions in the interferon sensitivity-determining region (ISDR) (P = .0036) correlated significantly with the response to interferon therapy. Because mutations analyzed by direct sequencing of polymerase chain reaction (PCR) products may reflect artifacts of direct sequencing, we further analyzed quasispecies of HCV in this region by cloning and sequencing. Although PCR-based analysis of responders with multiple amino acid substitutions in the ISDR showed the presence of a small amount of wild-type strain in their serum, the results obtained by direct sequencing and cloning were essentially the same. A longitudinal study of quasispecies in 2 patients who showed a dramatic change in the virus titer showed no conversion from wild type to mutant or vice versa. Our results indicate that amino acid substitutions and virus load are independent predictors of the response to interferon therapy. The ability of some patients with no mutation in the ISDR or high virus load to eliminate the virus suggests the presence of other unidentified factors, host or viral, that influence the response to interferon therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049229     DOI: 10.1002/hep.510250342

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  45 in total

1.  Management of chronic hepatitis C and prevention of hepatocellular carcinoma.

Authors:  Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

Review 2.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

Review 3.  Genetics of IL28B and HCV--response to infection and treatment.

Authors:  C Nelson Hayes; Michio Imamura; Hiroshi Aikata; Kazuaki Chayama
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-29       Impact factor: 46.802

Review 4.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

5.  Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.

Authors:  Itaru Ozeki; Jun Akaike; Yoshiyasu Karino; Tomohiro Arakawa; Yasuaki Kuwata; Takumi Ohmura; Takahiro Sato; Naohiro Kamiya; Ichimaro Yamada; Kazuaki Chayama; Hiromitsu Kumada; Joji Toyota
Journal:  J Gastroenterol       Date:  2011-05-10       Impact factor: 7.527

6.  Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.

Authors:  K Sandres; M Dubois; C Pasquier; J L Payen; L Alric; M Duffaut; J P Vinel; J P Pascal; J Puel; J Izopet
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 7.  Sequence diversity of hepatitis C virus: implications for immune control and therapy.

Authors:  Joerg Timm; Michael Roggendorf
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

8.  Efficacy of interferon treatment for chronic hepatitis C predicted by feature subset selection and support vector machine.

Authors:  Jun Yang; Anto Satriyo Nugroho; Kazunobu Yamauchi; Kentaro Yoshioka; Jiang Zheng; Kai Wang; Ken Kato; Susumu Kuroyanagi; Akira Iwata
Journal:  J Med Syst       Date:  2007-04       Impact factor: 4.460

Review 9.  Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities.

Authors:  Tetsuro Shimakami; Robert E Lanford; Stanley M Lemon
Journal:  Curr Opin Pharmacol       Date:  2009-09-15       Impact factor: 5.547

10.  Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response.

Authors:  Cíntia Bittar; Ana Carolina G Jardim; Lilian H T Yamasaki; Artur T L de Queiróz; Claudia M A Carareto; João Renato R Pinho; Isabel Maria V G de Carvalho-Mello; Paula Rahal
Journal:  BMC Infect Dis       Date:  2010-02-23       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.